Clinical Trial Search

Primary: AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for Unchanged SYR-472 (SYR-472Z) — 2733; 2780 nanogram hour per…

Primary: Diagnostic — 1.57; 1.57; 1.55; 1.56 Z-score — p=0.981

Primary: Percentage of Participants Who Maintained Average Hemoglobin (Hb) Concentration Within Plus Minus (+/-) 1 Grams Per Deciliter (g/dL) of Their Reference Hb and Between 10…

Primary: Number of Subjects With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 subjects

Primary: Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide — 8.05; 8.21; 7.43; 16.71 μg/mL

Primary: Percentage of Non-cirrhotic, Treatment-naive Participants in Each Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 75.0; 91.5…

Primary: Mean Serum Adalimumab Concentration at Week 8 — 7.99; 10.0 μg/mL

Primary: The Primary Endpoint is the Total Dose of Glucocorticoids Administered Between Baseline and the End of Treatment. — 124; 135 mg/kg

Primary: Percentage Surface Microhardness Recovery (%SMHR) of Placebo Dentifrice/Fluoride Rinse Compared to Placebo Dentifrice/No Rinse — 24.48; 8.09 % SMHR — p=<0.0001

Primary: Progression Free Survival — 3.75; 3.68 months

Primary: Effect of Change in Body Mass Index on Change in Grip Strength With Aromatase Inhibitor Therapy — -0.15; 2.44 kg/m^2 — p=0.03

Primary: Progression Free Survival (PFS) — 15.9; 10.7 weeks

Primary: Number of Patients With Improvement in Liver Histology After Treatment With Exenatide — 8 participants

Primary: Change From Baseline in Pain Intensity of Patient With Spinal Disorder as Measured by NRS. — -1.69 scores on a scale — p=<0.05

Primary: Percent Change From Baseline in Mean Lumbar Spine Bone Mineral Density (BMD) at Month 12 — 3.2; -0.1 percent change in BMD — p=<0.001